Actively Recruiting
New Taipei City Clinical Trials Using a Digital AI Platform to Improve Treatment of High Blood Pressure, High Blood Sugar, and High Cholesterol and Prevent Heart and Kidney Diseases
Led by New Taipei City Medical Association · Updated on 2026-05-14
4162
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate prevention and treatment strategies for chronic conditions known as the Three Highshypertension, hyperglycemia, and hyperlipidemiawhich are major contributors to cardiovascular disease and related complications in Taiwan. The program includes two large-scale cluster-randomized clinical trials within the New Taipei City healthcare network, designed to assess the impact of a mobile digital health platform and the timing of antihypertensive medication on blood pressure control, organ damage, and cardiovascular events. One trial T-888-DIGICARE compares standard care with an intervention using a mobile digital health platform enhanced with interactive modules to improve management of the Three Highs. The second trial DREAM-G investigates whether taking antihypertensive medications at bedtime versus in the morning better controls morning home blood pressure in patients with elevated morning readings. Participants undergo detailed blood pressure monitoring and medication adjustments based on a stepwise protocol targeting morning hypertension. Both trials include follow-up periods extending up to two years after enrollment. Participants will engage in regular home blood pressure monitoring using the 722 protocol and attend clinic visits for laboratory and imaging assessments at multiple time points over 24 months. Data collected include blood pressure, lipid levels, glucose control, kidney function, and signs of organ damage. The trials also feature AI-assisted analysis, lifestyle education, and digital communication tools to support therapy adherence and health management. Outcomes focus on blood pressure control, lipid and glucose targets, kidney and cardiovascular health, and safety monitoring throughout the study period.
CONDITIONS
Brief Title
New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases
Research Team
H
Hung-Shun Yen Principal Investigator
T
Tzung-Dau Wang Co-Principal Investigator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
